Payment overview · 2025
General Payments
$721.92
37 reported records · 12 companies
Healthcare provider profile · identity verified
Paul Anthony Jackson
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MURFREESBORO, TN · NPI 1285375543
Verified facts
What the public records show
CMS Open Payments records show Paul Anthony Jackson received $721.92 in general payments during 2025 across 37 reported records.
Novartis Pharmaceuticals Corporation accounted for 29.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $210.30 | 29.1% | 14 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $127.24 | 17.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $119.61 | 16.6% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $44.23 | 6.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.13 | 6.1% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $40.15 | 5.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.86 | 4.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.45 | 3.7% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $21.41 | 3.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.39 | 2.7% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $19.24 | 2.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.91 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $721.92 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $210.30 | 14 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $127.24 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $119.61 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $44.23 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.13 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $40.15 | 2 | 2025 |
Source payment records
|
|||||
| CORLANOR Normalized: corlanor |
Drug | Amgen Inc. | $28.83 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $26.45 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 264 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 256 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 240 | 33 |
| Furosemide | Furosemide | 176 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 171 | 30 |
| Sertraline Hcl | Sertraline Hcl | 155 | 23 |
| Omeprazole | Omeprazole | 154 | 24 |
| Gabapentin | Gabapentin | 148 | 29 |
| Donepezil Hcl | Donepezil Hcl | 129 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 22 |
| Buspirone Hcl | Buspirone Hcl | 122 | 22 |
| Losartan Potassium | Losartan Potassium | 113 | 19 |
| Trazodone Hcl | Trazodone Hcl | 112 | 23 |
| Mirtazapine | Mirtazapine | 106 | 16 |
| Famotidine | Famotidine | 104 | 13 |
| Olanzapine | Olanzapine | 100 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 15 |
| Eliquis | Apixaban | 95 | 21 |
| Lisinopril | Lisinopril | 93 | 20 |
| Potassium Chloride | Potassium Chloride | 93 | 20 |
| Metformin Hcl | Metformin Hcl | 86 | 15 |
| Alprazolam | Alprazolam | 85 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 81 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 74 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 71 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 11 |
| Memantine Hcl | Memantine Hcl | 62 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 58 | suppressed |
| Pregabalin | Pregabalin | 57 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 33 |
| Prednisone | Prednisone | 56 | 12 |
| Alendronate Sodium | Alendronate Sodium | 55 | suppressed |
| Allopurinol | Allopurinol | 55 | suppressed |
| Simvastatin | Simvastatin | 54 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 11 |
| Atenolol | Atenolol | 52 | suppressed |
| Lorazepam | Lorazepam | 52 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 49 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 47 | suppressed |
| Carvedilol | Carvedilol | 47 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 43 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | suppressed |
| Spironolactone | Spironolactone | 41 | suppressed |
| Glimepiride | Glimepiride | 40 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Meloxicam | Meloxicam | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 35 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Linzess | Linaclotide | 35 | 11 |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Lidocaine | Lidocaine | 32 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Carbamazepine Er | Carbamazepine | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 23 | suppressed |
| Azithromycin | Azithromycin | 23 | 19 |
| Latanoprost | Latanoprost | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 13 |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Mirabegron Er | Mirabegron | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $721.92 · 37 records | Novartis Pharmaceuticals Corporation | Auvelity, CORLANOR, LAGEVRIO, LEQVIO, LifeVest, MOUNJARO, NEXPLANON, Paradise Ultrasound Renal Denervation System, REPATHA, REXULTI, VERQUVO, Veozah, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error